Asbestos exposure may cause asbestosis, pleural plaques and benign pleural disease, and may pre-dispose to malignant mesothelioma and other neoplasms. The occurrence to two primary tumours in the same patient is rare, and the appearance of a pleural mesothelioma and another lung tumour is exceptional. The present case report describes a patient who, by standard immunohistochemistry, was thought to have mesothelioma at pleuro-pneumonectomy, and adenocarcinoma in the other lung at post-mortem 5 months later. Subsequent investigation using the MOC31 antibody demonstrated a single pathology of adenocarcinoma of the lung. The additional use of this antibody has important histopathogical and legal implications. 
Asbestos exposure may cause asbestosis, pleural plaques and benign pleural disease, and may pre-dispose to malignant mesothelioma and other neoplasms. The occurrence to two primary tumours in the same patient is rare, and the appearance of a pleural mesothelioma and another lung tumour is exceptional. The present case report describes a patient who, by standard immunohistochemistry, was thought to have mesothelioma at pleuro-pneumonectomy, and adenocarcinoma in the other lung at post-mortem 5 months later. Subsequent investigation using the MOC31 antibody demonstrated a single pathology of adenocarcinoma of the lung. The additional use of this antibody has important histopathogical and legal implications. malignant pleural mesothelioma and adenocarcinema of the lung. In that case, as in the present case, the tumours were differentiated by a panel of antibodies (CEA, B72.3, LEU, Ml), although MOC31 was not available (6) . In the present case, there was no evidence of the right lung carcinoma on the pre-operative thoracic CT scan. Prior to MOC31 immunohistochemistry, it appeared that a mesothelioma was the primary diagnosis, and on this basis, the widow of the deceased instigated legal proceedings to claim compensation. The action had to be discontinued when adenocarcinoma was found to be the sole cause of the left-sided pleural tumour and the right-sided pulmonary mass. Although both epithelioid pleural mesothelioma and adenocarcinoma of the lung have a poor outcome, their histological differentiation is vital as misdiagnosis is likely to affect treatment, prognosis and the result of claims for compensation. The distinction between these two tumours may be relatively straightforward on clinical and histological grounds, but in a small number of cases, immunohistochemical staining is required to determine the origin of poorly differentiated tumours. A large number of markers that are preferentially expressed in adenocarcinoma, compared to mesothelioma, are now available. No single marker can distinguish between the two pathologies. It has been demonstrated that reactivity to at least two of the three antibodies LEU Ml, CEA and B72.3 is present in all lung adenocarcinomas (7) . In a similar study by Brown et al., the best two markers were found to be CEA and B72.3 (both positive: 100% specific and 88% sensitive for adenocarcinoma; both negative 99% specific and 97% sensitive for mesothelioma) (8) . That work supported the original diagnosis of two pathologies in this case (Table 1) . MOC31 is a new reagent which recognizes a transmembrane glycoprotein present on most types of epithelial cell, including adenocarcinoma. It does not recognize normal or malignant mesothelial cells, and it has proved highly sensitive in differentiating adenocarcinoma from mesothelioma or reactive mesothelial cells in pleural or ascites cytological specimens (9) . In a recent study from the present authors' laboratory using MOC3 1 immunohistochemistry, 42 of 43 mesotheliomas were negative (the one exception probably a 'pseudomesotheliomatous' adenocarcinoma secondary to treatment for childhood lymphoma), and 43 of 44 adenocarcinomas were positive (the one exception being of indeterminate origin) (10) . Further unpublished work from the present authors' laboratory has shown the value of MOC31 in diagnosing adenocarcinoma in cases where Leu Ml was negative. Although the possibility that MOC 3 1 immunohistochemistry was erroneous in this case should be considered, pleural biopsy and surgical specimen were both positive and a single pathology is clinically more plausible.
It is still not understood how asbestos fibres cause malignancy, and it has been suggested that the rarity of simultaneous pleural mesothelioma and pulmonary adenocarcinoma is because different patho-physiological mechanisms are involved. This idea may be supported by the fact that carcinoma of the lung is more common in smokers with asbestosis. However, mesothelioma is not more common amongst smokers, and seems to be caused by asbestos exposure rather than asbestosis.
MOC31 appears to be a valuable addition to the panel of antibodies required to distinguish between some cases of mesothelioma and adenocarcinoma. In the case presented, it has played a pivotal role in reaching a diagnosis, and has important implications in claims for compensation for mesothelioma.
